Association of health-related quality of life (HRQOL) variations with biological biomarkers for patients with metastatic castrate-resistant prostate cancer (MCRPC) treated by abiraterone/prednisone combination or prednisone.

被引：0
|
作者：
Goujon, Morgan [1 ]
Anota, Amelie [2 ,3 ]
Charton, Frontczak Alexandre [4 ]
Charton, Emilie [5 ,6 ]
Maurina, Tristan [1 ]
Almotlak, Hamadi [1 ]
Nguyen, Thierry [1 ]
Fabien, Calcagno [1 ]
Stein, Ulrich [1 ]
Mouillet, Guillaume [7 ]
Thiery-Vuillemin, Antoine [8 ]
机构：
[1] Univ Hosp, Dept Med Oncol, Besancon, France
[2] Univ Hosp Besancon, Qual Life Oncol Clin Res Platform, Besancon, France
[3] Univ Hosp Besancon, Methodol & Qual Life Oncol, INSERM UMR 1098, Besancon, France
[4] Univ Hosp, Dept Urol, Besancon, France
[5] Univ Hosp Besancon, Methodol & Qual Life Unit, Dept Oncol, INSERM UMR 1098, Besancon, France
[6] French Natl Platform Qual Life & Canc, Besancon, France
[7] Univ Hosp, Dept Med Oncol, Methodol & Qual Life Unit Oncol, INSERM UMR 1098, Besancon, France
[8] Univ Hosp, Dept Med Oncol, INSERM UMR 1098, Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.54
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
54
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] Predictive Value of Early Prostate Specific Antigen (PSA) Response in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Treated With Post-Docetaxel Abiraterone
    Morley, Courtney
    Delahunty, Rachel
    Parente, Phillip
    Pezaro, Carmel
    Mant, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 130 - 130
  • [43] Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide
    Haas, Naomi B.
    LaRiviere, Michael J.
    Buckingham, Thomas H.
    Cherkas, Yauheniya
    Calara-Nielsen, Karl
    Foulk, Brad
    Patel, Jaymala
    Gross, Steven
    Smirnov, Denis
    Vaughn, David J.
    Amaravadi, Ravi
    Wellen, Kathryn E.
    Savitch, Samantha L.
    Majmundar, Krishna J.
    Black, Taylor A.
    Yee, Stephanie S.
    He, Miaoling
    Min, Eun Jeong
    Long, Qi
    Jones, Jeremy O.
    Pal, Sumanta K.
    Carpenter, Erica L.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) : 448 - 456
  • [44] Clustering of Health-Related Quality of Life (HRQoL) items in metastatic prostate cancer patients
    Martinelli, Francesca
    Quinten, Chantal
    Maringwa, John
    Coens, Corneel
    Cleeland, Charles
    Gotay, Carolyn
    Reeve, Bryce
    Ringash, Jolie
    Flechtner, Henning
    Greimel, Eva
    Osoba, David
    King, Madeleine
    Schmucker-Von Koch, Joseph
    Taphoorn, Martin
    Weis, Joachim
    Fossa, Sophie
    Albrecht, Walter
    Van Poppel, Hendrik
    Powell, Philip
    Johnson, Mark
    Bottomley, Andrew
    QUALITY OF LIFE RESEARCH, 2010, 19 : 127 - 127
  • [45] Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/prednisone (AA/P).
    Giridhar, Karthik
    Sosa, Carlos
    Sicotte, Hugues
    Wang, Liewei
    Wang, Liguo
    Sinnwell, Jason P.
    Tan, Winston
    Costello, Brian Addis
    Quevedo, Fernando
    Pitot, Henry C.
    Bryce, Alan Haruo
    Jimenez, Rafael E.
    Weinshilboum, Richard M.
    Dehm, Scott
    Kalari, Krishna R.
    Kohli, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide
    Naomi B. Haas
    Michael J. LaRiviere
    Thomas H. Buckingham
    Yauheniya Cherkas
    Karl Calara-Nielsen
    Brad Foulk
    Jaymala Patel
    Steven Gross
    Denis Smirnov
    David J. Vaughn
    Ravi Amaravadi
    Kathryn E. Wellen
    Samantha L. Savitch
    Krishna J. Majmundar
    Taylor A. Black
    Stephanie S. Yee
    Miaoling He
    Eun Jeong Min
    Qi Long
    Jeremy O. Jones
    Sumanta K. Pal
    Erica L. Carpenter
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 448 - 456
  • [47] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [48] TREATMENT PATTERN AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN THE UNITED STATES (US)
    Shore, Neal
    Karsh, Lawrence
    Shevrin, Daniel
    Symanowski, James
    Lin, Daniel
    Turner, Jeff
    Russell, David
    Song, Yi
    Spalding, James
    Negreiro, Filipa
    Penson, David
    JOURNAL OF UROLOGY, 2023, 209 : E382 - E382
  • [49] A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone
    Lin, Jianqing
    Sama, Ashwin Reddy
    Hoffman-Censits, Jean H.
    Kennedy, Brooke
    Kilpatrick, Deborah
    Ye, Zhong
    Yang, Hushan
    Mu, Zhaomei
    Leiby, Benjamin E.
    Lewis, Nancy
    Cristofanilli, Massimo
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).
    Saad, Fred
    Winquist, Eric
    Hubay, Stacey
    Berry, Scott R.
    Assi, Hazem
    Levesque, Eric
    Aucoin, Nathalie
    Czaykowski, Piotr
    Lattouf, Jean-Baptiste
    Alloul, Karine
    Stewart, John
    Sridhar, Srikala S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345